Invention Grant
- Patent Title: Meningococcus adhesins NadA, App and ORF 40
- Patent Title (中): 脑膜炎球菌粘附素NadA，App和ORF 40
-
Application No.: US14224031Application Date: 2014-03-24
-
Publication No.: US09249197B2Publication Date: 2016-02-02
- Inventor: Maria Arico , Maurizio Comanducci
- Applicant: Novartis Vaccines and Diagnostics SRL
- Applicant Address: BE Rixensart
- Assignee: GlaxoSmithKline Biologicals SA
- Current Assignee: GlaxoSmithKline Biologicals SA
- Current Assignee Address: BE Rixensart
- Agency: Morrison & Foerster LLP
- Priority: GB0118401.9 20010727; GB0121591.2 20010906; GB0211025.2 20020514
- Main IPC: C07K14/22
- IPC: C07K14/22 ; A61K39/00
Abstract:
NadA, App and ORF40 function as adhesins in N. meningitidis. Adhesion nad be modulated by targeting these three proteins. NadA allelic variants are also disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in E. coli. Mature App proteins are disclosed. Knockout mutants are disclosed. Vesicles from non-Neisserial hosts with heterologous adhesion expression are disclosed.
Public/Granted literature
- US20140294884A1 MENINGOCOCCUS ADHESINS NADA, APP AND ORF 40 Public/Granted day:2014-10-02
Information query
